Reports & White Papers
View the latest Biosimilars Council reports and white papers for detailed information about what biosimilars are, how they work and how they generate savings for patients and the health care system.
September 5, 2024
Report
The Biosimilars Council, alongside the Association for Accessible Medicines (AAM), released its 2024 U.S. Generic & Biosimilar Medicines Savings Report—highlighting... Read more »
December 18, 2023
Report
The 2023 U.S. Generic and Biosimilar Savings Report, the annual report from the Association for Accessible Medicines and its Biosimilars... Read more »
August 14, 2023
Report
The Biosimilars Council released a report that tracks the biosimilar insulin market and found that pharmacy benefit managers (PBMs) are... Read more »
September 21, 2022
Report
The 2022 U.S. Generic and Biosimilar Savings Report, the annual report from the Association for Accessible Medicines and its Biosimilars... Read more »
October 12, 2021
Report
The 2021 U.S. Generic and Biosimilar Medicines Savings Report, featuring data from IQVIA, proves that the promise of biosimilars is... Read more »
February 22, 2021
Whitepapers
The first in a series of papers, this paper examines the challenges to market sustainability for generic and biosimilar medicines... Read more »
September 28, 2020
Whitepapers
Following its first peer-reviewed scientific paper on biosimilar medicines development: the Path Towards Tailored Clinical Biosimilar Development (BioDrugs), the International... Read more »
July 16, 2020
Whitepapers
Biosimilars in the pharmacy benefit employers driving appropriate use and transparency. Despite the fact that less than 2 percent of... Read more »
June 3, 2020
Whitepapers
Alex Brill, Founder of Matrix Global Advisors (MGA), an economic consulting firm, and a Resident Fellow at AEI, details misconceptions... Read more »
September 9, 2019
Whitepapers
America’s health care system is eager for biosimilars, especially in light of mounting evidence that they deliver increased patient access... Read more »
June 25, 2019
Whitepapers
As prescription drug costs continue to increase, biosimilar medicines represent hope for patients seeking access to more affordable treatment. Biosimilars... Read more »
May 13, 2019
Council Resource
Whitepapers
Insulin has been available to America’s diabetes patients for decades. Millions rely on this medicine every day to control their... Read more »
July 25, 2018
Report
This annual report is produced by the IQVIA, the standard-bearer for measuring data, pharmaceutical use and spending in the United... Read more »
May 30, 2018
Report
Whitepapers
America’s patients who suffer from many complex and chronic diseases have promising new treatment options in biologic and specialty medicines.... Read more »
April 30, 2018
Report
Biologics are medicines extracted from a variety of natural sources—human, animal or microorganism—and include a wide range of products such... Read more »
July 6, 2017
Report
This annual report is produced by the IQVIA, the standard-bearer for measuring data, pharmaceutical use and spending in the United... Read more »